Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetoencephalography biomarkers for assessing myelin content and neuronal function in acute optic neuritis.

Brain communications·2026
Same author

Neuronal Activity Promotes Node-Like Cluster Assembly Prior to Myelination and Remyelination in the Central Nervous System.

Glia·2026
Same author

Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.

Neurology·2025
Same author

Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.

Frontiers in immunology·2024
Same author

Cerebellar encephalitis and peripheral neuropathy with an atypical clinical and neuroimaging signature following Covid-19 vaccine: a report of two cases.

Journal of neurology·2024
Same author

Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.

Multiple sclerosis and related disorders·2024

Related Experiment Video

Updated: Jun 2, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

[Multiple sclerosis: emerging treatments].

Catherine Lubetzki1

  • 1Département de Neurologie, Inserm 975 UPMC, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital - 75651 Paris cedex 13. catherine.lubetzki@psl.aphp.fr

Bulletin De L'Academie Nationale De Medecine
|May 17, 2011
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a central nervous system inflammatory disease causing disability in young adults. Current MS treatments show promise but have toxicity and are ineffective in progressive stages.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Related Experiment Videos

Last Updated: Jun 2, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Area of Science:

  • Neurology
  • Immunology
  • Neuroscience

Context:

  • Multiple sclerosis (MS) is a primary cause of non-traumatic neurological disability in young adults.
  • The disease involves central nervous system inflammation, demyelination, and axonal damage.
  • Existing therapies include immunomodulators, immunosuppressants, and natalizumab, targeting lymphocyte transmigration.

Purpose:

  • To review current therapeutic strategies for multiple sclerosis.
  • To evaluate the efficacy and toxicity of existing and emerging treatments.
  • To highlight the unmet need for treatments effective in the progressive phase of MS.

Summary:

  • Current multiple sclerosis treatments, including immunomodulators and natalizumab, offer encouraging efficacy in relapsing-remitting forms.
  • However, these treatments are associated with significant toxicities, such as severe infections.
  • Crucially, no current therapies have demonstrated effectiveness for the progressive phase of MS, where axonal damage is a key feature.

Impact:

  • Identifies limitations of current multiple sclerosis treatments, particularly in progressive disease.
  • Underscores the urgent need for novel therapeutic approaches targeting axonal protection and progressive neurodegeneration.
  • Informs future research directions for developing safer and more effective multiple sclerosis therapies.